Public Policy Resources

Share

As a recognized expert in cancer health policy, ACS CAN develops reports, white papers, testimony, fact sheets, regulatory comment letters and public policy on a wide range of issues related to preventing cancer and improving the health care system for persons with cancer and survivors.  We encourage you to use this resource to learn more about our issue priorities and policy work. If you can't find something you need, you may contact us by using our contact form and selecting Policy Resources from the drop-down menu.

Search for Resources

FILTER BY:

Photo of female cancer patient

Patient Quality of Life

ACS CAN advocates for policies that improve the lives of cancer patients by making treatment of their pain and other symptoms and coordination of their care standard protocol throughout their treatment for cancer, starting at the point of diagnosis.
 

Featured Resources

 

ACS CAN submitted comments to FDA regarding the use of opioids at higher doses, in response to an FDA request for comments. 

Photo of ACS CAN Volunteers at Advocacy Event to Support Cancer Research Funding

Research, Funding and Drug Development

Improvements in outcomes for cancer patients require continued research and innovation.  ACS CAN advocates for robust federal funding for cancer research, as well as research and drug approval policies that accelerate the development of new treatments while still ensuring patient safety.

ACS CAN provided comments on recent draft guidance issued by FDA intended to improve diversity of clinical trial participants.  Our comments built on recent consensus recommendation issued last year. 

The Henrietta Lacks Enhancing Cancer Research Act of 2019 directs GAO to evaluate federal policies and programs for their impact on enrollment in cancer clinical trials, with a focus on how underserved trial enrollment is impacted.  This letter expresses the support of over two dozen organization

ACS CAN responded to the reopening of the Centers for Medicare and Medicaid Services (CMS) coverage decision for NGS testing panels.  ACS CAN comments stressed that the existing coverage framework improperly freezes coverage based on current science rather than allowing a framework that could evo

Photo of ACS CAN Volunteers participating in health care reform Lobby Day event

Access to Health Care

ACS CAN advocates for policies that provide access to treatments and services people with cancer need for their care - including those who may be newly diagnosed, in active treatment and cancer survivors.

A Section 1115 Demonstration Waiver gives states flexibility to design and improve upon their Medicaid programs through pilot or demonstration projects.

"Surprise billing” is when an insured patient is unknowingly treated by an out-of-network provider and is then billed the difference between what the provider charged, and what the insurer paid. Surprise bills can be significantly higher than the consumer’s standard in-network cost-sharing. 

Photo of Making Strides Against Breast Cancer Event Participant

Prevention and Early Detection

ACS CAN advocates for public policies that can prevent nearly half of all cancer deaths by ensuring access to recommended cancer screenings, protecting the public from skin cancer risk, reducing tobacco use and exposure to secondhand smoke and supporting people in increasing physical activity, eating a healthy diet, and managing their weight.

The American Cancer Society (ACS) and the American Cancer Society Cancer Action Network (ACS CAN) respectfully submit the following comments on the Food and Drug Administration’s (FDA’s) comprehensive, multi-year Nutrition Innovation Strategy.  

Flavors are a marketing weapon the tobacco manufacturers use to target youth and young people to a lifetime of addiction. The use of any flavored tobacco product among youth is concerning because it exposes them to a lifetime of nicotine addiction, disease, and premature death.